Less than two weeks after snagging its first FDA nod for Imfinzi, AstraZeneca is out with more positive data for the checkpoint inhibitor. But this time, it’s positive data that could boost the entire immuno-oncology field.

AZ surprised the market Friday with rosy interim results from a trial testing Imfinzi as a maintenance therapy in surgery-ineligible patients with stage 3 non-small cell lung cancer. The med hit its primary endpoint in progression-free survival, and it’s the first in its class to do so in that setting.